Tucatinib and trastuzumab in HER2+ biliary tract cancer:
🔹️46.7% ORR, 1 CR
🔹️Median DoR: 6 months
🔹️Median PFS and OS: 5.5 and 15.5 months, respectively.
🔹️Chemo-free regimen
Very encouraging!
#ASCO23 #hpbcsm #CancerResearch

Emerald-1 TACE + Durva/bev vs + Durva vs TACE
PFS : 15 vs 10 vs 8 (+ve for Durva/bev arm, HR:0.77)
Good design that the role of each component could be delineated! #GI24 #livertwitter #hpbcsm
Bevacizumab is essential/ Benefit of durvalumab alone is surprisingly limited

Less than 4 weeks to #ASCO23 - countdown is on
Great #GI lineup including #PROSPECT plenary
My list of #abstracts I will be watching for
#CRCsm #HPBCsm #STCsm #PANCsm
ASCO

IMBRAVE050

Adjuvant Atezo➕BEV

For hepatocellular cancer (HCC) #HPBCSM .

OncoAlert #ASCO23

78% 🆚 65% 12 month RFS rate.

What do folks think? Good enough as an endpoint or wait till OS data?

Continuing HER2 story in biliary tract cancers, bispecific Ab Zanidatamab (HERIZON-BTC-01):
⚡️ORR: 41.3%, 1 CR
⚡️Median DoR: 12.9 months 🔥
⚡️Median PFS: 5.5 months, OS not mature
Most common AEs: diarrhea, infusion reactions, rare cardiac events
#ASCO23 #hpbcsm #CancerResearch

Exciting data from ReFocus in small numbers for FGFR2 inhibition in Cholangiocarcinoma with RLY-4008. ORR: 73% with nearly 1 year duration of response in FGFR inhibitor-naive pts with fusions.
#ASCO23 #hpbcsm #CancerResearch

Excited to see updates on the ReFocus trial of FGFR2 inhibitor RLY-4008 in Cholangiocarcinoma and solid tumors!

Still open at Cleveland Clinic!

#ASCO23 #hpbcsm #CancerResearch

To all oncologists,

It's vital to recognize: “Patients with resectable disease have better outcomes, and you can’t account for that without randomizing.” #hncsm

This truth is universal across ALL disease sites! #blcsm #esocsm #hpbcsm #kcsm #lcsm

#radonc #surgonc #ESTRO24

#GI23 ASCO #ClinicalTrials

Adjuvant after surgical resection.

Locoregional➕💊

TACE➕Sorafenib

#HCC #HPBCSM OncoAlert

👇🏾Not surprising to see that occurrence of immune related adverse events (iRAEs) has an impact on survival for patients with hepatocellular cancer (HCC) getting the new STRIDE regimen.

T3️⃣0️⃣0️⃣➕D

#HPBCSM #ASCO23 OncoAlert

Most iRAEs within 3-months.

OS: 23m🆚14.1m

#COHO23 #Whistler
Howie reviewing systemic therapy updates in #HCC #livercancer …and there lots to update! #HPBCsm
BC Cancer

Minimally invasive robotic surgery can offer several benefits over conventional open surgery.

Learn about the evolution of robotic surgery at NYU Langone Hospital—Long Island from our #hpbcsm and #pancsm surgical oncologist, Dr. Megan Winner: bit.ly/45kwgDl

#ASCO23

👇🏾TIGIT⛔️ TIRAGOlumab

Addition to the Atezo➕BEV backbone for #hepatocellular cancer (HCC).

Complexity of the interconnections in the immune axis. Ghassan Abou-Alfa dissecting the data & putting things into context.

💡MORPHEUS platform.

#HPBCSM #ASCO23 OncoAlert

Honoured to be a member of the inaugural Editorial Board for ESMO Gastrointestinal Oncology with this amazing 🌎 group of GI oncology researchers 🙏 🇨🇦
⭐️will be an important platform to highlight & disseminate rapid advances in GI Oncology
#crcsm #esosm #hpbcsm #pcsm #stcsm

🌟🌟🌟 In DESTINY-PanTumor02, Trastuzumab deruxtecan showed durable responses across HER2-expressing solid tumors ➡️ brnw.ch/21wFvEs #gyncsm #hpbcsm #blcsm MD Anderson Cancer Center

🎯Tucatinib and trastuzumab yields efficacy in previously treated HER2–Positive metastatic #BiliaryTractCancer 👉 brnw.ch/21wE5Zu #hpbcsm

Alcohol use is often associated with #LiverCancer , but in most cases, other factors are to blame. Mayo Clinic hepatologist Sumera Ilyas talks about the increase in liver cancer incidence, treatment options and more in this Mayo Clinic Q&A: bit.ly/3YSzz1o #hpbcsm

Thank you @fsgimt for this invite to comment on TOPAZ-1 by our Cancer at Cedars-Sinai star #hemeonc fellow Dr. Matthew Ebia and #GI onc team Dr. Andrew Hendifar Kamya Sankar MD Arsen Osipov, MD #hpbcsm #cholangiocarcinoma Cedars-Sinai Academic Medicine @CedarsSinai pubmed.ncbi.nlm.nih.gov/36950948/

Updates on GI oncology including #pancsm #crcsm #hpbcsm to be presented by Joseph Herman MD, MSc, MSHCM at Northwell's Best of Radiation Oncology next week! Register here: ccevent.site/2023-01-13-ro/…
#radonc PanCAN #pancreaticcancer Pancreatic Cancer UK Anuj Goenka MD Louis Potters, MD

Guidelines recommend consideration of adjuvant #capecitabine for resected #biliarytractcancer despite absence of significant improvement in survival. This article places the results of the #BILCAP trial in context. #hpbcsm David J. Benjamin, MD Vinay Prasad MD MPH doi.org/10.1093/oncolo…